Dive Brief:
David Davidson, a longtime top executive at gene therapy developer Bluebird bio, will join the richly funded biotech startup Tessera Therapeutics as its chief medical and development officer, the latter company announced Wednesday.
At Tessera, Davidson will be joined by former Spark Therapeutics and Moderna executive Hari Pujar, who will become chief operating officer, and by Lin Guey, most recently a vice president at Xilio Therapeutics who has been appointed head of rare disease strategy and operations.
Launched by Flagship Pioneering last year, Tessera in January raised $230 million to advance its development of a new, more flexible type of genetic medicine, which the company and its venture backer have dubbed gene writing.